1. A Phase 1 Trial of Eltrombopag in Patients Undergoing Stem Cell Transplantation after Total Body Irradiation 
Jane L. Liesveld, Gordon L. Phillips, Michael Becker, Louis S. Constine, Jonathan Friedberg, Jeffrey R. Andolina, Laurie A. Milner, Jessica DeBolt, Therese Smudzin, Ollivier Hyrien, Connie L. Erickson-Miller, Brendan M. Johnson, Katie-Louise Dawson, Yuhchyau Chen 
Biology of Blood and Marrow Transplantation 
Volume 19, Issue 12, Pages (December 2013)
DOI: /j.bbmt
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Time to platelet engraftment according to the CIBMTR definition for each patient (A) and number of platelet transfusions required up to day 100 (B). Bar shading distinguishes distinct dosing cohorts as defined in the brackets.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Mean ± SEM plasma eltrombopag concentration by dose level after single-dose administration (A, first dose) and at steady state (B, dose during week 2).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
The mean ± SEM serum TPO levels as measured by ELISA at the indicated time points (n = 15 to 16). None of these levels was significantly different from baseline as assessed by a 2-way mixed ANOVA model.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions